Join
Live feed
·
PRReleasevia Quantisnow
Kezar Life Sciences Inc. logo

Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis

ByQuantisnow·Wall Street's wire, on your screen.
KZR· Kezar Life Sciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KZR (Kezar Life Sciences Inc.) and more on Quantisnow.